trial

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCTId NCT05208190
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 280 (estimated)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2028-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
280 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2022-03-17
Primary completion
2028-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Clozapine

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Ragy R Girgis, MDPrincipal Investigator

Sites

7 total
Los Angeles, United StatesAugusta, United StatesBaltimore, United StatesNew York, United StatesNew York, United StatesNew York, United StatesChapel Hill, United States

Facts & assertions

4 sourced
Enrollment
280
Phase
PHASE4
Primary Completion Date
2028-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Clozapine
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Ragy R Girgis, MD
person